Table 1.
Demographics and baseline characteristics of participants ≥60 years of age and overall population
| Overall pooled population | Participants ≥60 years of age | |||||
|---|---|---|---|---|---|---|
| Quarterly fremanezumab n = 943 |
Monthly fremanezumab n = 954 |
Placebo n = 945 |
Quarterly fremanezumab n = 74 |
Monthly fremanezumab n = 92 |
Placebo n = 80 |
|
| Age, years, mean (SD) | 42.8 (11.83) | 43.0 (12.09) | 42.9 (12.02) | 63.5 (2.96) | 63.2 (3.15) | 64.0 (2.83) |
| Female, n (%) | 811 (86) | 813 (85) | 808 (86) | 60 (81) | 77 (84) | 67 (84) |
| White, n (%) | 787 (83) | 804 (84) | 787 (83) | 71 (96) | 81 (88) | 70 (88) |
| BMI, kg/m2, mean (SD) | 26.3 (4.98) | 26.0 (4.94) | 26.4 (4.81) | 25.5 (4.14) | 25.7 (4.18) | 26.0 (4.01) |
| Migraine classification, n (%) | ||||||
| Chronic migraine | 545 (58) | 553 (58) | 541 (57) | 56 (76) | 46 (50) | 45 (56) |
| Episodic migraine | 398 (42) | 401 (42) | 404 (43) | 18 (24) | 46 (50) | 35 (44) |
| Time since initial migraine diagnosis, years, mean (SD) | 21.1 (12.77) | 21.5 (12.88) | 21.2 (12.92) | 37.3 (13.06) | 38.0 (12.31) | 37.1 (12.49) |
SD, standard deviation; BMI, body mass index